期刊文献+

Graves病对骨矿物质代谢的影响 被引量:2

The influence of Graves disease on bone mineral metabolism
下载PDF
导出
摘要 目的通过骨密度测定以及骨代谢指标检测技术了解,甲状腺功能亢进性骨病的特征,探讨Graves病对骨矿物质代谢的影响。方法测定96例Graves病患者和35例正常对照者的血清FT3、FT4、TSH浓度、血清骨钙素(BGP)、血钙、血磷、尿羟脯胺酸(HOP)浓度和骨密度(BMD)。结果Graves病患者组血清FT3、FT4浓度高于正常对照组(P<0.01);血清BGP、尿HOP浓度与血清FT3浓度呈正相关(r=0.35,P<0.05;r=0.34,P<0.05),明显高于缓解组和正常对照组(P<0.01);血钙、血磷浓度均高于正常对照组(P<0.01);患者组L2~4、股骨颈、Ward's三角和大转子的骨密度均低于正常对照组(P<0.01);患者骨量丢失发生率为41%(39/96)。结论Graves病可导致骨矿物质代谢紊乱,并发骨量丢失和骨质疏松,应早发现及时治疗。 Aim Along with the development of BMD and bone metabolic marker measurement technologies, it has been given more attention in bone mineral metabolism changes result from hyperthyroidism. In this paper we investigate the influence of Graves disease on bone mineral metabolism.Methods Total 96 patients with Graves disease diagnosed by serum FT3,FT4,TSH examination and 35 normal subjects were studied.The markers of bone mineral metabolism including serum BGP, calcium, phosphorus and urinary HOP were measured by radioimmunoassay and biochemistry respectively.Bone mineral density(BMD) was studied using dual energy x ray absorptiometry.Results The FT3,FT4 level in Graves disease group were higher than normal group;The correlation between serum BGP,urinary HOP and FT3 in Graves disease group were positive (r=0.35,P< 0.05; r=0.34,P< 0.05) and higher than normal group significantly; serum calcium, phosphorus in Graves disease group were also higher than normal group(P< 0.01). The BMD of lumber 2~ 4, femoral neck,greater trochanter and Ward's triangle were lower than normal group; the bone loss happened in Graves disease patients was 41% (39/96).Conclusion The Graves disease may result in disturbance of bone mineral metabolism, complicating bone mineral material loss and osteoporosis finally. <P>
出处 《中国临床康复》 CSCD 2003年第9期1400-1401,共2页 Chinese Journal of Clinical Rehabilitation
基金 江苏省医学重点人才科研基金(35RC2002035)~~
关键词 GRAVES病 骨矿物质代谢 测定 骨密度 甲状腺功能亢进性骨病 血清 骨钙素 Graves' disease bone density metabolism bone osteoporsis
  • 相关文献

参考文献1

共引文献2

同被引文献14

  • 1Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;337(23):1641- 7 被引量:1
  • 2Ettinger B, Black DM, Mitlak BH,et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637- 453 被引量:1
  • 3Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene(LY13948)HCI: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11(6):835- 42 被引量:1
  • 4Delmas PD,Ensrud KE, Adachi JD.et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four year results from a randomized clinical trial.J Clin Endocrinol Mettab 2002;87(8):3609- 17 被引量:1
  • 5Lufkin EG, Whitaker MD, Nickelsen T,et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13(11):1747- 54 被引量:1
  • 6矫杰 孟迅吾 夏维波.雷诺昔芬防治骨质疏松的研究进展 [J].骨质疏松和矿盐疾病基础与临床,2003,2(3):181-4. 被引量:2
  • 7李长贵,宁光,彭怡文,江曼丽,陈家伦.胰岛素、胰岛素原对胰岛素抵抗状态下HepG2细胞PAI-1分泌的影响[J].中华内分泌代谢杂志,1998,14(4):240-243. 被引量:14
  • 8朱汉民.防治骨质疏松症非性激素类药物进展[J].国外医学(内分泌学分册),2003,23(2):108-110. 被引量:22
  • 9汪大望,周素彬.Graves病患者单能X射线测定骨密度研究[J].中国骨质疏松杂志,2003,9(1):40-42. 被引量:1
  • 10陈莲珍,田莉,贾新颖,王育琴.骨质疏松症药物治疗的临床评价[J].中国临床康复,2003,7(12):1803-1804. 被引量:14

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部